Market Overview

UPDATE: Credit Suisse Initiates Jazz Pharmaceuticals with Outperform, $65 PT; Organic and Acquisition Growth Outlook

Related JAZZ
Jazz Pharmaceuticals Up On Allergan, Inc. Rumor
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs

Credit Suisse initiates its coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Outperform rating and a price target of $65.

Credit Suisse comments, "We rate JAZZ Outperform because it offers (1) organic growth of the Xyrem franchise, driven by volume growth, pricing power and what we see as a defensible franchise against generics until at least 2020, based on our work with patent counsel; (2) diversification, accretion and cash flows provided by Erwinaze, the key product obtained in the recently announced EUSA acquisition; and (3) a platform for acquisitions created by JAZZ's low tax rate, focused acquisition strategy and execution capabilities."

JAZZ closed at $43.66 on Tuesday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Aug 2014JP MorganInitiates Coverage onOverweight
Jul 2014Buckingham ResearchInitiates Coverage onBuy
Jul 2014SunTrust Robinson HumphreyInitiates Coverage onNeutral

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (JAZZ)

Around the Web, We're Loving...

Get Benzinga's Newsletters